A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation.

Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2012 Planned number (27) of patients added as reported by European Clinical Trials Database record.
    • 03 Mar 2011 Planned end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 23 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top